On August 28, Cytokinetics fell 6.03% in regular trading, trading at $73.465/share, with turnover of $11.94 million.

On the news front, the company presented full results from its ACACIA-HCM Phase 3 trial at the European Society of Cardiology Congress, simultaneously published in The New England Journal of Medicine. The trial demonstrated statistically significant improvements across both patient-reported symptoms (KCCQ-CSS) and exercise capacity endpoints in non-obstructive hypertrophic cardiomyopathy over 36 weeks. The company plans to submit a supplemental new drug application to the FDA in Q4.

However, the decline reflects a classic sell-the-news dynamic. Top-line results were initially disclosed in early May, when shares surged over 20%. The current ESC presentation and NEJM publication provided detailed confirmatory data rather than new information. The stock extended a 1.6% loss from the prior session, suggesting investors had already priced in the positive outcome. RBC previously estimated the nHCM indication could add approximately $1.3 billion in incremental U.S. revenue for the drug Myqorzo.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)